The abstract, titled Results of a randomized placebo-controlled double-blind adaptive Phase 2 study (AKITA) evaluating RMC-035 for the prevention of AKI in patients undergoing cardiac surgery, will be presented at a late-breaking clinical trial poster session on
The abstract includes the recently announced results from the Phase 2 clinical study AKITA, which demonstrated statistically significant and clinically relevant long-term kidney-protective effects of RMC-035 after open-heart surgery.
“We are pleased to be presenting important clinical trial results of RMC-035 at such a large and reputable conference as the ASN Kidney Week. The results represent a potential breakthrough in the protection of kidney function in open-heart surgery and we are looking forward to advancing RMC-035 in the clinical development towards an approved medication,” said Tobias Agervald, CEO at
About RMC-035
RMC-035 represents a completely new class of drugs (first-in-class) and consists of a recombinant and modified variant of the endogenous protein alpha-1-microglobulin. The investigational drug protects cells and their mitochondria from damage caused by oxygen deprivation and elevated levels of the oxygen-binding and toxic protein heme. Favorable treatment effects of RMC-035 have been observed in several preclinical disease models. RMC-035 has a natural affinity for the kidneys and is primarily being developed as an intravenous kidney protective treatment for patients undergoing open-heart surgery at high risk of developing kidney injury.
RMC-035 has obtained an Investigational New Drug (IND) clearance by the
© Modular Finance, source